Abstract
Prostate cancer is a public health problem in industrialized countries because of a high incidence. Unequal access to health care and identified risk factors could explain the difference of incidence between different parts of the world. Incidence is different worldwide; it is especially high in African peoples. In countries with low incomes, advanced stages are more often observed, but more aggressive disease is also frequent. Prognosis is based on serum PSA level, clinical stage, and histological Gleason score. The standard treatment of localized disease is radical prostatectomy. In advanced disease, the first-line treatment is androgen deprivation therapy. All these treatments have consequences on sexual activity.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Cancer Registry Guadeloupe and Martinique (2008–2010). http://www.sentinelles971.com/le-registre-general-des-cancers-de-guadeloupe/
Multigner L, Ndong JR, Giusti A, Romana M, Delacroix-Maillard H, Cordier S, Jégou B, Thome JP, Blanchet P (2010) Chlordecone exposure and risk of prostate cancer. J Clin Oncol 28(21):3457–3462
Cancel-Tassin G, Cussenot O (2005) Genetic susceptibility to prostate cancer. BJU Int 96(9):1380–1385
Emeville E, Broquère C, Brureau L, Ferdinand S, Blanchet P, Multigner L, Romana M (2014) Copy number variation of GSTT1 and GSTM1 and the risk of prostate cancer in a Caribbean population of African descent. PLoS One 9(9):e107275
Cancel-Tassin G, Romana M, Gaffroy C, Blanchet P, Cussenot O, Multigner L (2014) Region 2 of 8q24 is associated with the risk of aggressive prostate cancer in Caribbean men of African descent from Guadeloupe (French West Indies). Asian J Androl 16:1–3
Zong Y, Goldstein AS, Huang J (2013) The molecular basis for ethnic variation and histological subtype differences in prostate cancer. Sci China Life Sci 56(9):780–787
Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O’Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD, PLCO Project Team (2009) Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360(13):1310–1319
Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Páez A, Määttänen L, Bangma CH, Aus G, Carlsson S, Villers A, Rebillard X, van der Kwast T, Kujala PM, Blijenberg BG, Stenman UH, Huber A, Taari K, Hakama M, Moss SM, de Koning HJ, Auvinen A, ERSPC Investigators (2012) Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 366(11):981–990
D’Amico AV, Whittington R, Malkowicz SB, Fondurulia J, Chen MH, Tomaszewski JE, Wein A (1998) The combination of preoperative prostate specific antigen and postoperative pathological findings to predict prostate specific antigen outcome in clinically localized prostate cancer. J Urol 160:2096–2101
Klotz L, Vesprini D, Sethukavalan P, Jethava V, Zhang L, Jain S, Yamamoto T, Mamedov A, Loblaw A (2015) Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol. 33(3):272–277
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Blanchet, P., Brureau, L. (2015). Prostate Cancer. In: Droz, JP., Carme, B., Couppié, P., Nacher, M., Thiéblemont, C. (eds) Tropical Hemato-Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-18257-5_40
Download citation
DOI: https://doi.org/10.1007/978-3-319-18257-5_40
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-18256-8
Online ISBN: 978-3-319-18257-5
eBook Packages: MedicineMedicine (R0)